Join the Oncology Voice Network. Join for Free
Bringing the Real Patient Voice to Oncology Decisions

Bringing the Real Patient Voice to Oncology Decisions


Share This Article


Who truly speaks for the patient when they’re not there to speak for themselves?

In this eye-opening episode of Oncology Voice Network, host Dr. Kirk Shepard is joined by Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy for Oncology at Sanofi. Drawing on a career spanning frontline social work, policy, nonprofit advocacy, and industry leadership, Elizabeth Franklin reveals the real reasons the “patient voice” often gets lost when critical decisions are made in cancer care. Go beyond surface-level buzzwords as they unpack where patient advocacy can break through organizational resistance, how early decisions in drug development either open doors or shut them, and why it’s not enough to listen—true impact requires action and systemic redesign. Discover the micro and macro shifts the industry can no longer afford to delay, and what it actually takes to carry real patient insight into rooms of power.

If you care about moving oncology forward, don’t miss this powerful conversation. Tune in now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Explore OVN